7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2019-03-31 2018-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2009-06-30 2009-03-31 2008-12-31 2008-09-30 2008-06-30 2008-03-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-09-30 2005-06-30 2005-03-31 2004-09-30 2004-06-30 2004-03-31 
      
    		                                                         
      revenue:
    		                                                         
      commercial revenue:
    		                                                         
      product sales
    		31,792,000 19,273,000 6,287,000                                                       
      royalty revenue
    		75,694,000 69,952,000 64,166,000                                                       
      other commercial revenue
    		8,112,000 13,531,000 5,715,000 12,103,000 13,152,000 11,512,000 20,013,000 16,977,000 16,828,000 16,885,000                                                
      total commercial revenue
    		115,598,000 102,756,000 76,168,000 85,716,000 75,731,000 72,036,000 59,593,000 78,845,000 84,081,000 77,897,000 67,768,000 80,479,000 72,410,000 78,184,000 72,285,000 68,088,000                                          
      research and development revenue:
    		                                                         
      collaborative agreement revenue
    		31,436,000 336,921,000 45,031,000 96,894,000 44,883,000 141,524,000 49,345,000 179,144,000 44,167,000 91,013,000 38,334,000 49,940,000 69,250,000 38,247,000 49,784,000                                           
      wainua joint development revenue
    		9,685,000 12,372,000 10,413,000 43,966,000 13,200,000 11,690,000 10,559,000                                                   
      total research and development revenue
    		41,121,000 349,293,000 55,444,000 140,860,000 58,083,000 153,214,000 59,904,000 245,660,000 60,126,000 110,514,000 62,756,000 71,410,000 87,357,000 55,607,000 69,634,000                                           
      total revenue
    		156,719,000 452,049,000 131,612,000 226,576,000 133,814,000 225,250,000 119,497,000 324,505,000 144,207,000 188,411,000 130,524,000 151,889,000 159,767,000 133,791,000 141,919,000 297,214,000 32,325,000 44,063,000 57,076,000 28,161,000 42,249,000 23,585,000 38,092,000 43,360,000 19,873,000 11,601,000 47,340,000 23,235,000 32,403,000 20,713,000 24,823,000 21,147,000 26,420,000 28,624,000 23,503,000 29,926,000 32,262,000 26,771,000 30,992,000 31,576,000 20,661,000 32,215,000 32,961,000 21,354,000 38,631,000 3,813,000 2,450,000 11,945,000 3,253,000 4,375,000 4,958,000 7,458,000 105,929,843,000 7,442,000 9,093,000 9,843,000 12,303,000 
      yoy
    		17.12% 100.69% 10.14% -30.18% -7.21% 19.55% -8.45% 113.65% -9.74% 40.82% -8.03% -48.90% 394.25% 203.64% 148.65% 955.41% -23.49% 86.83% 49.84% -35.05% 112.59% 103.30% -19.54% 86.62% -38.67% -43.99% 90.71% 9.87% 22.65% -27.64% 5.62% -29.34% -18.11% 6.92% -24.16% -5.23% 56.15% -16.90% -5.97% 47.87% -46.52% 744.87% 1245.35% 78.77% 1087.55% -12.85% -50.58% 60.16% -100.00% -41.21% -45.47% -24.23% 860908.23%     
      qoq
    		-65.33% 243.47% -41.91% 69.32% -40.59% 88.50% -63.18% 125.03% -23.46% 44.35% -14.07% -4.93% 19.42% -5.73% -52.25% 819.46% -26.64% -22.80% 102.68% -33.35% 79.14% -38.08% -12.15% 118.19% 71.30% -75.49% 103.74% -28.29% 56.44% -16.56% 17.38% -19.96% -7.70% 21.79% -21.46% -7.24% 20.51% -13.62% -1.85% 52.83% -35.87% -2.26% 54.36% -44.72% 913.14% 55.63% -79.49% 267.20% -25.65% -11.76% -33.52% -99.99% 1423305.58% -18.16% -7.62% -20.00%  
      expenses:
    		                                                         
      cost of sales
    		2,338,000 4,151,000 1,463,000 3,830,000 1,071,000 4,164,000 2,151,000 3,062,000 2,191,000 2,537,000 1,343,000 3,686,000 1,515,000 4,745,000 4,170,000                                           
      gross profit
    		154,381,000 447,898,000 130,149,000 222,746,000 132,743,000 221,086,000 117,346,000 321,443,000 142,016,000 185,874,000 129,181,000 148,203,000 158,252,000 129,046,000 137,749,000                                           
      yoy
    		16.30% 102.59% 10.91% -30.70% -6.53% 18.94% -9.16% 116.89% -10.26% 44.04% -6.22%                                               
      qoq
    		-65.53% 244.14% -41.57% 67.80% -39.96% 88.41% -63.49% 126.34% -23.60% 43.89% -12.84% -6.35% 22.63% -6.32%                                            
      gross margin %
    		98.51% 99.08% 98.89% 98.31% 99.20% 98.15% 98.20% 99.06% 98.48% 98.65% 98.97% 97.57% 99.05% 96.45% 97.06% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
      research, development and patent
    		217,754,000 217,460,000 200,759,000 245,490,000 219,761,000 222,064,000 214,215,000 256,555,000 215,330,000 229,927,000 197,813,000 308,272,000 182,990,000 180,758,000 161,126,000 106,417,000                                          
      selling, general and administrative
    		96,809,000 90,622,000 76,250,000 88,079,000 61,638,000 65,113,000 52,644,000 71,011,000 69,951,000 46,142,000 45,516,000 47,950,000 34,416,000 33,802,000 34,127,000 68,221,000                         3,301,500 4,571,000 4,899,000 3,736,000 4,278,000 3,089,000 3,402,000 4,520,000 2,823,000         
      total operating expenses
    		316,901,000 312,233,000 278,472,000 337,399,000 282,470,000 291,341,000 269,010,000 330,628,000 287,472,000 278,606,000 244,672,000 359,908,000 218,921,000 219,305,000 199,423,000 175,679,000 46,777,750 65,556,000 63,726,000 57,828,000 62,107,000 49,090,000 46,020,000 41,735,000 45,992,000 39,647,000 43,644,000 41,690,000 51,019,000 43,029,000 38,883,000 37,255,000 42,278,000 37,571,000 42,175,000 34,806,000 43,933,000 37,167,000 35,819,000 32,218,000 17,433,000 36,539,000 36,094,000 30,185,000 28,574,000 23,473,000 23,351,000 28,681,000 21,517,000 21,477,000 20,974,000 19,602,000 2,351,531,183,000 30,949,000 31,473,000 31,183,000 34,638,000 
      income from operations
    		 139,816,000 -146,860,000 -110,823,000 -148,656,000 -66,091,000 -149,513,000 -6,123,000 -143,265,000 -90,195,000 -114,148,000 -208,019,000 -59,154,000 -85,514,000 -57,504,000 121,535,000 -14,452,750 -21,493,000 -6,650,000 -29,667,000    1,625,000   3,696,000                  10,057,000             
      yoy
    		 -311.55% -1.77% 1709.95% 3.76% -26.72% 30.98% -97.06% 142.19% 5.47% 98.50% -271.16% 309.29% 297.87% 764.72% -509.66%    -1925.66%                                      
      qoq
    		 -195.20% 32.52% -25.45% 124.93% -55.80% 2341.83% -95.73% 58.84% -20.98% -45.13% 251.66% -30.83% 48.71% -147.31% -940.91% -32.76% 223.20% -77.58%                                       
      operating margin %
    		 30.93% -111.59% -48.91% -111.09% -29.34% -125.12% -1.89% -99.35% -47.87% -87.45% -136.95% -37.03% -63.92% -40.52% 40.89% -44.71% -48.78% -11.65% -105.35% 0%   3.75% 0%  7.81%  0%    0%    0%    0%    26.03%   0%          
      other income:
    		                                                         
      investment income
    		23,682,000 24,687,000 24,667,000 28,910,000 26,228,000 25,599,000 26,285,000 25,686,000 23,935,000 20,792,000 18,627,000 11,884,000 7,524,000 3,403,000 1,993,000 12,142,000 500,750 675,000 671,000 657,000 685,000 434,000 589,000 376,000 359,000 408,000 477,000 600,000 518,000 575,000 616,000 705,000 780,000 776,000 859,000 955,000 1,118,000 1,430,000 1,678,000 2,192,000 -1,743,000 7,546,000 560,000 4,956,000 2,603,000 3,053,000 3,401,000 2,123,000 1,682,000 1,344,000 811,000 1,241,000 349,842,000 504,000 561,000 842,000 1,133,000 
      interest expense
    		  -4,108,000 -4,191,000 -4,161,000 -4,490,000 -4,151,000 -4,558,000 -4,203,000 -2,291,000 -1,608,000 -1,731,000 -2,139,000 -2,130,000 -2,122,000 -11,599,000 -3,725,500 -4,998,000 -4,961,000 -4,943,000                                      
      interest expense related to sale of future royalties
    		  -18,822,000 -18,669,000 -18,533,000 -18,296,000 -17,959,000 -17,849,000 -17,779,000 -17,655,000 -15,515,000                                               
      gain on investments
    		29,908,000  -2,164,000 -80,250 879,000 -3,533,000 2,333,000 -161,000 -1,943,000 718,000  3,283,000 2,347,000 -6,337,000   168,750 538,000 -260,000 397,000 305,000 175,000 840,000 1,058,000 1,446,000  2,000 17,000  18,000 34,000      -710,000 123,000 2,612,000       1,989,000 1,521,000   2,263,000        
      other income
    		363,000 102,000 465,000 314,000 142,000 610,000 277,000 399,000 2,447,000 11,183,000 230,000 -1,980,750 4,713,000 -12,297,000 187,000                                           
      income before income tax benefit
    		 123,531,000  -107,039,000 -144,101,000       -44,330,000 -46,709,000    -17,508,750 -25,278,000  -33,556,000                                      
      income tax benefit
    		 20,000  2,690,000 3,621,000       -8,100,000 -283,000    -500 -1,398,000 -881,000 2,276,000 -523,000 5,193,000 1,181,000 64,000 8,405,000 706,000           1,156,250 3,968,000  717,000                  
      net income
    		 123,551,000 -146,938,000 -104,349,000 -140,480,000 -66,265,000 -142,803,000 -9,263,000 -147,410,000 -85,290,000 -124,323,000 -52,430,000 -46,992,000 -105,135,000 -65,165,000 90,884,000 -17,509,250 -26,676,000 -12,081,000 -31,280,000 -24,276,000 -24,570,000 -10,126,000 -1,672,000 -2,637,000 -37,639,000 -1,207,000 -23,995,000 -16,191,250 -26,882,000 -17,889,000 -19,994,000     -8,445,000   170,930,000  3,188,000   20,007,000             
      yoy
    		 -286.45% 2.90% 1026.51% -4.70% -22.31% 14.86% -82.33% 213.69% -18.88% 90.78% -157.69% 168.38% 294.12% 439.40% -390.55% -27.87% 8.57% 19.31% 1770.81% 820.59% -34.72% 738.94% -93.03% -83.71% 40.02% -93.25% 20.01%                              
      qoq
    		 -184.08% 40.81% -25.72% 112.00% -53.60% 1441.65% -93.72% 72.83% -31.40% 137.12% 11.57% -55.30% 61.34% -171.70% -619.06% -34.36% 120.81% -61.38% 28.85% -1.20% 142.64% 505.62% -36.59% -92.99% 3018.39% -94.97% 48.20% -39.77% 50.27% -10.53%                           
      net income margin %
    		 27.33% -111.64% -46.05% -104.98% -29.42% -119.50% -2.85% -102.22% -45.27% -95.25% -34.52% -29.41% -78.58% -45.92% 30.58% -54.17% -60.54% -21.17% -111.08% -57.46% -104.18% -26.58% -3.86% -13.27% -324.45% -2.55% -103.27% -49.97% -129.78% -72.07% -94.55% 0%    -26.18%   541.33% 0% 9.90% 0% 0% 51.79% 0% 0% 0% 0% 0% 0%       
      basic and diluted net income per share
    		  -0.93 -0.66 -0.95 -0.45 -0.98 -0.06 -1.03 -0.6 -0.87 -0.37 -0.33 -0.74 -0.46  -0.15 -0.23 -0.1 -0.27 -0.22 -0.21 -0.09 -0.02 -0.02 -0.37 -0.01 -0.24 -0.163 -0.27 -0.18          -0.01 0.03 -0.02 -0.05 -1.25 -0.13 -0.16 -0.18 -0.16 -0.03 -0.24 -0.24  -0.52 -0.57 -0.47 -0.47 
      shares used in computing basic and diluted net income per share
    		159,765  158,735 2,811 148,593 145,958 145,538 138 143,317 143,098 142,735 66 141,950 141,794 141,599  29,377.75 117,811 117,588 117,128 1,894 115,263 108,539 101,875 225 100,680 100,213 100,157 36 99,687 99,602 99,569 42 99,196 99,091 99,013       94,675 90,799 83,942 82,548 82,456 1,374 73,588 72,822 72,377 64,086 5,752,456,111 57,521 57,267 56,111 55,858 
      loss on investments
    		          -529,000    -6,625,000                                           
      basic net income per share
    		 0.78              0.63                                          
      diluted net income per share
    		 0.7              0.62                                          
      shares used in computing basic net income per share
    		 159,137              138,582                     24,497 98,320 98,116 97,521 23,446.5 95,863                
      shares used in computing diluted net income per share
    		 182,331              141,537                     24,497 98,320 98,116 111,274 23,446.5 100,181                
      income before income tax expense
    		  -146,822,000   -66,201,000 -142,728,000 -82,799,500 -140,808,000 -77,448,000 -112,943,000   -102,875,000 -64,071,000 121,931,000   -11,200,000                                       
      income tax expense
    		  -116,000   -64,000 -75,000 -6,456,250 -6,602,000 -7,842,000 -11,380,000   -2,260,000 -1,094,000 -31,047,000                                          
      spinraza royalties
    		   63,684,000 57,208,000 56,743,000 38,455,000 61,868,000 67,253,000 61,012,000 50,247,000 67,222,000 61,647,000 59,627,000 53,818,000 59,711,000                                          
      wainua royalties
    		   9,929,000 5,371,000 3,781,000 1,125,000                                                   
      eplontersen joint development revenue
    		       14,970,750 15,959,000 19,501,000 24,422,000 21,470,000 18,107,000 17,360,000 19,850,000                                           
      tegsedi and waylivra revenue
    		          6,478,000 7,584,000 5,920,000 10,386,000 6,160,000                                           
      licensing and other royalty revenue
    		          11,043,000 5,673,000 4,843,000 8,171,000 12,307,000 1,623,000                                          
      tegsedi product sales
    		               6,754,000                                          
      research and development revenue under collaborative agreements
    		               229,126,000 29,993,750 43,798,000 56,628,000 19,550,000 41,276,000 23,383,000 37,615,000 41,921,000 19,015,000 11,127,000 47,140,000 21,818,000 31,682,000 20,189,000 24,305,000 20,014,000 25,437,000 27,785,000 21,143,000 28,556,000 21,716,000 25,962,000 30,768,000 29,685,000 20,114,000 31,240,000 26,814,000 20,686,000 11,921,000 3,482,000 2,002,000 3,831,000 2,469,000 4,322,000 4,468,000 7,122,000 104,388,217,000 7,135,000 9,055,000 8,217,000 6,998,000 
      cost of products sold
    		               1,041,000                                          
      other incomes
    		               -147,000                                          
      net (income) loss attributable to noncontrolling interest in akcea therapeutics, inc.
    		               -6,441,000                                          
      net income attributable to ionis pharmaceuticals, inc. common stockholders
    		               84,443,000                                          
      licensing and royalty revenue
    		                2,331,250 265,000 448,000 8,611,000 973,000 202,000 477,000 1,439,000 858,000 474,000 200,000 1,417,000 721,000 524,000 518,000 1,133,000 983,000 839,000 2,360,000 1,370,000 10,546,000 809,000 224,000 1,891,000 547,000 975,000 6,147,000 668,000 26,710,000 331,000 448,000 8,114,000 784,000 53,000 490,000 336,000 1,541,626,000 307,000 38,000 1,626,000 5,305,000 
      research, development and patent expenses
    		                240,802,000 61,086,000 59,264,000 53,448,000 57,430,000 45,660,000                                    
      general and administrative
    		                3,328,250 4,470,000 4,462,000 4,380,000 4,677,000 3,430,000 3,389,000 3,423,000 3,234,000 3,096,000 3,209,000 2,976,000 3,800,000 3,105,000 2,874,000 3,010,000 2,945,000 2,855,000 3,051,000 2,819,000 3,830,000 3,335,000 3,673,000 3,677,000          2,710,000 2,566,000 1,724,000 19,102,568,000 2,137,000 2,373,000 2,568,000 2,453,000 
      equity in net income of regulus therapeutics inc.
    		                                                         
      loss on early retirement of debt
    		                                                         
      research and development
    		                      42,631,000 38,312,000 42,758,000 36,551,000 40,435,000 38,714,000 47,219,000 39,924,000 36,009,000 34,245,000 39,333,000 34,716,000 39,124,000 31,987,000 40,103,000 33,832,000 32,146,000 28,541,000 16,828,000 31,968,000 31,195,000 26,449,000 24,296,000 20,384,000 19,949,000 24,240,000 18,973,000 18,982,000 18,372,000 18,212,000 2,095,032,036,000 22,361,000 29,566,000 32,036,000 28,947,000 
      basic and diluted net income
    		                               -200                          
      income from continuing operations, before income tax expense
    		                                                         
      net income from continuing operations
    		                                    -0.21 -0.07 -0.03                   
      discontinued operations:
    		                                                         
      income from discontinued operations
    		                                                         
      gain on sale of ibis biosciences, inc., net of tax
    		                                    13,884,000   171,773,000                  
      net income from discontinued operations, net of tax
    		                                    13,884,000   171,744,000                  
      net income attributable to noncontrolling interest in regulus therapeutics inc.
    		                                    1,487,000 1,136,000 857,000 913,000                  
      net income attributable to isis pharmaceuticals, inc. common stockholders
    		                                -13,986,000 -12,454,000 -25,154,000 -9,658,000 -6,958,000 -6,924,000 -2,896,000 171,843,000                  
      basic and diluted net income per share:
    		                                                         
      net income from continuing operations attributable to isis pharmaceuticals, inc. common stockholders
    		                                -0.14 -0.13 -0.25 -0.1                      
      net income from discontinued operations
    		                                    0.14   1.76                  
      basic and diluted net income attributable to isis pharmaceuticals, inc. common stockholders
    		                                -0.14 -0.13 -0.25 -0.1 -0.07 -0.07                    
      income from continuing operations, before income tax benefit
    		                                                         
      net income from continuing operations, net of income tax benefit
    		                                                         
      basic net income per share:
    		                                                         
      basic net income attributable to isis pharmaceuticals, inc. common stockholders
    		                                      -0.03 1.76                  
      diluted net income per share:
    		                                                         
      diluted net income attributable to isis pharmaceuticals, inc. common stockholders
    		                                      -0.03 1.57                  
      loss attributed to noncontrolling interest in symphony genisis, inc.
    		                                            8,748,000 7,603,000 6,806,000 5,085,250 6,733,000 13,608,000        
      loss attributed to noncontrolling interest in regulus therapeutics llc
    		                                        764,000 1,208,000 965,000 883,000 87,000             
      loss attributed to noncontrolling interest in ibis biosciences, inc.
    		                                        290,750 267,000 791,000 105,000              
      excess purchase price over carrying value of noncontrolling interest in symphony genisis, inc.
    		                                                         
      net income applicable to common stock
    		                                        -8,658,000 3,188,000 -2,208,000 -4,285,000 -105,304,000 -11,024,000 -13,020,000 -14,146,000 -12,105,000 -2,172,000 -17,480,000 -15,172,000  -29,658,000 -32,708,000 -26,129,000 -26,487,000 
      restructuring activities
    		                                                  36,000  650,000 7,084,000    
      net income before noncontrolling interest in symphony genisis, inc.
    		                                                         
      operating expenses:
    		                                                         
      compensation expense/(benefit) related to variable accounting of stock options
    		                                                         
      compensation benefit related to variable accounting of stock options
    		                                                         
      compensation benefit related to stock options
    		                                                   15,000 5,000     
      accretion of dividends on preferred stock
    		                                                         
      compensation expense related to stock options
    		                                                        3,238,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.